e-learning
resources
Milan 2017
Wednesday, 13.09.2017
Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
New and repurposed TB drugs use in children and adolescents with M/XDR-TB
A. Skrahina (Minsk region, Belarus)
Source:
International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Session:
Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Session type:
Oral Presentation
Number:
4853
Disease area:
Paediatric lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Skrahina (Minsk region, Belarus). New and repurposed TB drugs use in children and adolescents with M/XDR-TB. 4853
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
New and repurposed drugs for MDR-TB patients
Source: International Congress 2017 – PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence
Year: 2017
New approaches to MDR/XDR TB chemotherapy in children and adolescents
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019
Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
Source: Eur Respir J 2016; 48: 938-943
Year: 2016
Effectiveness of treatment for MDR TB in children and adolescents
Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases
Year: 2007
Active tuberculosis case-finding among drug users and homeless persons: after the outbreak
Source: Eur Respir J 2016; 48: 269-271
Year: 2016
Management of drug resistant pulmonary TB. New problems and perspectives
Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis
Year: 2009
Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Challenges in TB treatment in children
Source: International Congress 2014 – PG20 Global evaluation of tuberculosis from children to adults
Year: 2014
Preventive chemotherapy effectiveness in children and adolescents, contacting TB patients with DR TB strains
Source: Eur Respir J 2006; 28: Suppl. 50, 536s
Year: 2006
New guidelines to manage MDR-TB
Source: School Course 13
Year: 2013
Spreading of resistance to group A anti-tuberculosis drugs among TB patients in Astana city
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
New anti-tuberculosis drugs for special populations: a difficult-to-address issue
Source: Eur Respir J 2016; 48: 957-958
Year: 2016
Rational use of new TB drugs in the EU
Source: Annual Congress 2012 - New guidelines in respiratory infections
Year: 2012
New anti-tuberculosis drugs and regimens: 2015 update
Source: ERJ Open Res 2015; 1: 00010-2015
Year: 2015
New perspectives in MDR-TB management
Source: International Congress 2016 – China Session II
Year: 2016
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Challenges in TB treatment in adults
Source: International Congress 2014 – PG20 Global evaluation of tuberculosis from children to adults
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept